Sugi Predict

Sugi Predict / Targets / SLC22A12

SLC22A12

Solute carrier family 22 member 12 · Q96S37 · SLC22A12 on Sugi Atlas →

56,428 patent compounds predicted against SLC22A12, 24,174 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL322237 SCHEMBL322237 0.78 20/20
SCHEMBL95728 SCHEMBL95728 0.68 17/20
SCHEMBL249261 SCHEMBL249261 0.66 17/20
SCHEMBL248724 SCHEMBL248724 0.62 17/20
SCHEMBL249022 SCHEMBL249022 0.78 16/20
SCHEMBL248867 SCHEMBL248867 0.66 15/20
SCHEMBL247372 SCHEMBL247372 0.54 15/20
SCHEMBL282352 SCHEMBL282352 0.51 15/20
SCHEMBL248221 SCHEMBL248221 0.65 14/20
SCHEMBL250383 SCHEMBL250383 0.60 14/20
SCHEMBL422146 SCHEMBL422146 0.58 14/20
SCHEMBL177096 SCHEMBL177096 0.51 14/20
SCHEMBL65955 SCHEMBL65955 0.50 14/20
SCHEMBL515097 SCHEMBL515097 0.50 13/20
SCHEMBL96355 SCHEMBL96355 0.63 12/20
SCHEMBL253614 SCHEMBL253614 0.62 12/20
SCHEMBL249359 SCHEMBL249359 0.51 12/20
SCHEMBL163330 SCHEMBL163330 0.60 11/20
SCHEMBL515098 SCHEMBL515098 0.50 11/20
SCHEMBL460443 SCHEMBL460443 1.00 9/20

Clinical trials — most relevant to SLC22A12 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use PHASE4COMPLETED
Genetic Basis for Variation in the Renal Elimination of Metformin PHASE4COMPLETED
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation PHASE2/PHASE3UNKNOWN
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome PHASE2RECRUITING
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) PHASE2COMPLETED
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery PHASE2COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias PHASE1COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
Cancer and Hearing Loss Related in Children nanCOMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only nanENROLLING_BY_INVITATION
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides nanCOMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient nanUNKNOWN
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
Genetics of Hyperuricemia Therapy in Hmong nanCOMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia nanCOMPLETED
Bile Acid Effects in Fetal Arrhythmia Study nanUNKNOWN
Autonomic Function in Patients With COPD nanCOMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
SLC13A5 Deficiency Natural History Study - United States Only nanENROLLING_BY_INVITATION
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL nanCOMPLETED
Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia nanCOMPLETED
Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population nanCOMPLETED
Impact of Genetics on Metformin Pharmacokinetics nanCOMPLETED
Effect of Pharmacogenetics on Imatinib Plasma Level and Response nanCOMPLETED
Characterization of Breg Cells nanCOMPLETED
Cardiovascular Effects of Empagliflozine nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC22A12 binder may also engage these)

ProteinNameSimilarity
SLC22A11 Solute carrier family 22 member 11 0.991 landscape →
Q8CFZ5 — 0.983 Q8CFZ5 →
Q3ZAV1 — 0.980 Q3ZAV1 →
Q4W8A3 — 0.956 Q4W8A3 →
Q5RCH6 — 0.955 Q5RCH6 →
SLC22A6 Solute carrier family 22 member 6 0.952 landscape →
Q2KIV1 — 0.950 Q2KIV1 →
Q9TSY7 — 0.949 Q9TSY7 →
A0A8B7HA97 — 0.946 A0A8B7HA97 →
Q8IVM8 — 0.937 Q8IVM8 →
Q864Z3 — 0.937 Q864Z3 →
Q6T423 — 0.936 Q6T423 →
A6NKX4 — 0.935 A6NKX4 →
Q63ZE4 — 0.933 Q63ZE4 →
Q9BYW1 — 0.931 Q9BYW1 →
Q8MK48 — 0.928 Q8MK48 →
Q8VCA0 — 0.923 Q8VCA0 →
Q5RC45 — 0.922 Q5RC45 →
Q8WUG5 — 0.918 Q8WUG5 →
A0A3Q2IDB4 — 0.918 A0A3Q2IDB4 →
Q8VC69 — 0.916 Q8VC69 →
Q8N4F4 — 0.915 Q8N4F4 →
Q76M99 — 0.913 Q76M99 →
O35956 — 0.911 O35956 →
G1SZD9 — 0.909 G1SZD9 →
O95528 — 0.908 O95528 →
Q6ZMD2 — 0.908 Q6ZMD2 →
Q6NUT3 — 0.907 Q6NUT3 →
Q1RPP5 — 0.905 Q1RPP5 →
ADAM33 Disintegrin and metalloproteinase domain-containing protein 33 0.905 landscape →